New study tracks rare bone disease to unlock clues for better diagnosis

NCT ID NCT07390240

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 4 times

Summary

This study is observing 55 children and adults in Russia who have hypophosphatasia (HPP), a rare genetic bone disease. Researchers will track symptoms, lab results, and quality of life to learn how the disease naturally progresses. No treatments are being tested—the goal is to gather information that could improve future diagnosis and care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors recognize and diagnose HPP earlier, improving care for patients.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly help participants. Results may not apply to people outside Russia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypophosphatasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOPHOSPHATASIA

Contacts and locations

Locations

Research Site
RECRUITING

Moscow, Russia
Research Site
RECRUITING

Rostov-on-Don, Russia
Research site
COMPLETED

Moscow, Russia
Research site
RECRUITING

Saint Petersburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.